Q-omics provides the consensus-scored SRIP3 profile across patient tissues and cancer cell-line models. SRIP3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SRIP3 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, SRIP3 RNA expression shows 5,425 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight MESO, COAD, and READ as cancer lineages where SRIP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRIP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRIP3 survival associations across molecular data types. SRIP3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRIP3 RNA expression–survival associations across cancer types. High SRIP3 expression shows unfavorable associations in MESO, LUSC, UCEC and SKCM, but favorable associations in COAD and SARC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SRIP3 RNA expression.
This table summarizes SRIP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SRIP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRIP3 shows higher tumor expression in COAD and HNSC. The COAD box plot shows higher SRIP3 RNA expression in tumor versus normal tissue (log2 FC = +1.141, t-test p < 0.001).
This table shows molecular features associated with SRIP3 in patient tissues and cancer cell lines. In patient samples, SRIP3 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
